Search

Your search keyword '"Mottet, Christian"' showing total 205 results
Start Over Author "Mottet, Christian" Language english
205 results on '"Mottet, Christian"'

2. Impact of Overweight and Obesity on Disease Outcome in the Pediatric Swiss Inflammatory Bowel Disease Cohort

Author

von Graffenried, Thea, Schoepfer, Alain M., Rossel, Jean-Benoit, Greuter, Thomas, Safroneeva, Ekaterina, Godat, Sébastien, Henchoz, Sarah, Vavricka, Stephan R., Sokollik, Christiane, Spalinger, Johannes, Braegger, Christian P., Nydegger, Andreas, Abdelrahman, Karim, Ademi, Gentiana, Aepli, Patrick, Thomas, Amman, Anderegg, Claudia, Antonino, Anca-Teodora, Archanioti, Eva, Arrigoni, Eviano, de Jong, Diana Bakker, Balsiger, Bruno, Bastürk, Polat, Bauerfeind, Peter, Becocci, Andrea, Belli, Dominique, Bengoa, José M., Biedermann, Luc, Binek, Janek, Blattmann, Mirjam, Boehm, Stephan, Boldanova, Tujana, Borovicka, Jan, Braegger, Christian P., Brand, Stephan, Brügger, Lukas, Brunner, Simon, Bühr, Patrick, Burnand, Bernard, Burk, Sabine, Burri, Emanuel, Buyse, Sophie, Cao, Dahlia-Thao, Carstens, Ove, Criblez, Dominique H., Cunningham, Sophie, D’Angelo, Fabrizia, de Saussure, Philippe, Degen, Lukas, Delarive, Joakim, Doerig, Christopher, Dora, Barbara, Drerup, Susan, Egger, Mara, El-Wafa, Ali, Engelmann, Matthias, Felley, Christian, Fliegner, Markus, Fournier, Nicolas, Fraga, Montserrat, Franc, Yannick, Frei, Pascal, Frei, Remus, Fried, Michael, Froehlich, Florian, Furlano, Raoul Ivano, Garzoni, Luca, Geyer, Martin, Girard, Laurent, Girardin, Marc, Golay, Delphine, Good, Ignaz, Bigler, Ulrike Graf, Gysi, Beat, Haarer, Johannes, Halama, Marcel, Haldemann, Janine, Heer, Pius, Heimgartner, Benjamin, Helbling, Beat, Hengstler, Peter, Herzog, Denise, Hess, Cyrill, Heyland, Klaas, Hinterleitner, Thomas, Hirschi, Claudia, Hruz, Petr, Juillerat, Pascal, Khalid-de Bakker, Carolina, Kayser, Stephan, Keller, Céline, Knellwolf, Christina, Knoblauch, Christoph, Köhler, Henrik, Koller, Rebekka, Krieger, Claudia, Künzler, Patrizia, Kusche, Rachel, Lehmann, Frank Serge, Macpherson, Andrew, Maillard, Michel H., Manz, Michael, Marot, Astrid, Meier, Rémy, Meyenberger, Christa, Meyer, Pamela, Michetti, Pierre, Misselwitz, Benjamin, Mosler, Patrick, Mottet, Christian, Müller, Christoph, Müllhaupt, Beat, Musso, Leilla, Neagu, Michaela, Nichita, Cristina, Niess, Jan, Nydegger, Andreas, Obialo, Nicole, Ollo, Diana, Oropesa, Cassandra, Peter, Ulrich, Peternac, Daniel, Petit, Laetitia Marie, Pittet, Valérie, Pohl, Daniel, Porzner, Marc, Preissler, Claudia, Raschle, Nadia, Rentsch, Ronald, Restellini, Alexandre, Restellini, Sophie, Richterich, Jean-Pierre, Ris, Frederic, Risti, Branislav, Ritz, Marc Alain, Rogler, Gerhard, Röhrich, Nina, Rossel, Jean-Benoît, Rueger, Vanessa, Rusticeanu, Monica, Sagmeister, Markus, Saner, Gaby, Sauter, Bernhard, Sawatzki, Mikael, Scharl, Michael, Schelling, Martin, Schibli, Susanne, Schlauri, Hugo, Schluckebier, Dominique, Schmid, Daniela, Schmid, Sybille, Schnegg, Jean-François, Schoepfer, Alain, Seematter, Vivianne, Seibold, Frank, Seirafi, Mariam, Semadeni, Gian-Marco, Senning, Arne, Sokollik, Christiane, Sommer, Joachim, Spalinger, Johannes, Spangenberger, Holger, Stadler, Philippe, Staub, Peter, Staudenmann, Dominic, Stenz, Volker, Steuerwald, Michael, Straumann, Alex, Stulz, Andreas, Sulz, Michael, Tatu, Aurora, Tempia-Caliera, Michela, Thorens, Joël, Truninger, Kaspar, Tutuian, Radu, Urfer, Patrick, Vavricka, Stephan, Viani, Francesco, Vögtlin, Jürg, Von Känel, Roland, Vouillamoz, Dominique, Vulliamy, Rachel, Wiesel, Paul, Wiest, Reiner, Wöhrle, Stefanie, Zamora, Samuel, Zander, Silvan, Zeitz, Jonas, and Zimmermann, Dorothee

Published
2022
Full Text
View/download PDF

3. Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals

Author

Anderegg, Claudia, Bauerfeind, Peter, Beglinger, Christoph, Begré, Stefan, Belli, Dominique, Bengoa, José M., Biedermann, Luc, Bigler, Beat, Binek, Janek, Blattmann, Mirjam, Boehm, Stephan, Borovicka, Jan, Braegger, Christian P., Brunner, Nora, Bühr, Patrick, Burnand, Bernard, Burri, Emanuel, Buyse, Sophie, Cremer, Matthias, Criblez, Dominique H., de Saussure, Philippe, Degen, Lukas, Delarive, Joakim, Doerig, Christopher, Dora, Barbara, Dorta, Gian, Egger, Mara, Ehmann, Tobias, El-Wafa, Ali, Engelmann, Matthias, Ezri, Jessica, Felley, Christian, Fliegner, Markus, Fournier, Nicolas, Fraga, Montserrat, Frei, Pascal, Frei, Remus, Fried, Michael, Froehlich, Florian, Funk, Christian, Furlano, Raoul Ivano, Gallot-Lavallée, Suzanne, Geyer, Martin, Girardin, Marc, Golay, Delphine, Grandinetti, Tanja, Gysi, Beat, Haack, Horst, Haarer, Johannes, Helbling, Beat, Hengstler, Peter, Herzog, Denise, Hess, Cyrill, Heyland, Klaas, Hinterleitner, Thomas, Hiroz, Philippe, Hirschi, Claudia, Hruz, Petr, Iwata, Rika, Jost, Res, Juillerat, Pascal, Keller, Céline, Knellwolf, Christina, Knoblauch, Christoph, Köhler, Henrik, Koller, Rebekka, Krieger-Grübel, Claudia, Kullak-Ublick, Gerd, Künzler, Patrizia, Landolt, Markus, Lange, Rupprecht, Lehmann, Frank Serge, Macpherson, Andrew, Maerten, Philippe, Maillard, Michel H., Manser, Christine, Manz, Michael, Marbet, Urs, Marx, George, Matter, Christoph, Meier, Rémy, Mendanova, Martina, Michetti, Pierre, Misselwitz, Benjamin, Morell, Bernhard, Mosler, Patrick, Mottet, Christian, Müller, Christoph, Müller, Pascal, Müllhaupt, Beat, Münger-Beyeler, Claudia, Musso, Leilla, Nagy, Andreas, Neagu, Michaela, Nichita, Cristina, Niess, Jan, Nydegger, Andreas, Obialo, Nicole, Oneta, Carl, Oropesa, Cassandra, Peter, Ueli, Peternac, Daniel, Petit, Laetitia Marie, Piccoli-Gfeller, Franziska, Pilz, Julia Beatrice, Pittet, Valérie, Raschle, Nadia, Rentsch, Ronald, Restellini, Sophie, Richterich, Jean-Pierre, Rihs, Sylvia, Ritz, Marc Alain, Roduit, Jocelyn, Rogler, Daniela, Rogler, Gerhard, Rossel, Jean-Benoît, Rueger, Vanessa, Saner, Gaby, Sauter, Bernhard, Sawatzki, Mikael, Schäppi, Michela, Scharl, Michael, Scharl, Sylvie, Schelling, Martin, Schibli, Susanne, Schlauri, Hugo, Uebelhart, Sybille Schmid, Schnegg, Jean-François, Schoepfer, Alain, Seibold, Frank, Seirafi, Mariam, Semadeni, Gian-Marco, Semela, David, Senning, Arne, Sidler, Marc, Sokollik, Christiane, Spalinger, Johannes, Spangenberger, Holger, Stadler, Philippe, Steuerwald, Michael, Straumann, Alex, Straumann-Funk, Bigna, Sulz, Michael, Suter, Alexandra, Thorens, Joël, Tiedemann, Sarah, Tutuian, Radu, Vavricka, Stephan, Viani, Francesco, Vögtlin, Jürg, Von Känel, Roland, Vonlaufen, Alain, Vouillamoz, Dominique, Vulliamy, Rachel, Wermuth, Jürg, Werner, Helene, Wiesel, Paul, Wiest, Reiner, Wylie, Tina, Zeitz, Jonas, Zimmermann, Dorothee, Pittet, Valérie E.H., and Simonson, Thomas

Published
2019
Full Text
View/download PDF

5. Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease

Author

Anderegg, Claudia, Bauerfeind, Peter, Beglinger, Christoph, Begré, Stefan, Belli, Dominique, Bengoa, José M., Biedermann, Luc, Bigler, Beat, Binek, Janek, Blattmann, Mirjam, Boehm, Stephan, Borovicka, Jan, Braegger, Christian P., Brunner, Nora, Bühr, Patrick, Burnand, Bernard, Burri, Emanuel, Buyse, Sophie, Cremer, Matthias, Criblez, Dominique H., de Saussure, Philippe, Degen, Lukas, Delarive, Joakim, Doerig, Christopher, Dora, Barbara, Dorta, Gian, Egger, Mara, Ehmann, Tobias, El-Wafa, Ali, Engelmann, Matthias, Ezri, Jessica, Felley, Christian, Fliegner, Markus, Fournier, Nicolas, Fraga, Montserrat, Frei, Pascal, Frei, Remus, Fried, Michael, Froehlich, Florian, Funk, Christian, Ivano Furlano, Raoul, Gallot-Lavallée, Suzanne, Geyer, Martin, Girardin, Marc, Golay, Delphine, Grandinetti, Tanja, Gysi, Beat, Haack, Horst, Haarer, Johannes, Helbling, Beat, Hengstler, Peter, Herzog, Denise, Hess, Cyrill, Heyland, Klaas, Hinterleitner, Thomas, Hiroz, Philippe, Hirschi, Claudia, Hruz, Petr, Iwata, Rika, Jost, Res, Juillerat, Pascal, Kessler Brondolo, Vera, Knellwolf, Christina, Knoblauch, Christoph, Köhler, Henrik, Koller, Rebekka, Krieger-Grübel, Claudia, Kullak-Ublick, Gerd, Künzler, Patrizia, Landolt, Markus, Lange, Rupprecht, Serge Lehmann, Frank, Macpherson, Andrew, Maerten, Philippe, Maillard, Michel H., Manser, Christine, Manz, Michael, Marbet, Urs, Marx, George, Matter, Christoph, McLin, Valérie, Meier, Rémy, Mendanova, Martina, Meyenberger, Christa, Michetti, Pierre, Misselwitz, Benjamin, Moradpour, Darius, Morell, Bernhard, Mosler, Patrick, Mottet, Christian, Müller, Christoph, Müller, Pascal, Müllhaupt, Beat, Münger-Beyeler, Claudia, Musso, Leilla, Nagy, Andreas, Neagu, Michaela, Nichita, Cristina, Niess, Jan, Noël, Natacha, Nydegger, Andreas, Obialo, Nicole, Oneta, Carl, Oropesa, Cassandra, Peter, Ueli, Peternac, Daniel, Marie Petit, Laetitia, Piccoli-Gfeller, Franziska, Beatrice Pilz, Julia, Pittet, Valérie, Raschle, Nadia, Rentsch, Ronald, Restellini, Sophie, Richterich, Jean-Pierre, Rihs, Sylvia, Alain Ritz, Marc, Roduit, Jocelyn, Rogler, Daniela, Rogler, Gerhard, Rossel, Jean-Benoît, Sagmeister, Markus, Saner, Gaby, Sauter, Bernhard, Sawatzki, Mikael, Schäppi, Michela, Scharl, Michael, Schelling, Martin, Schibli, Susanne, Schlauri, Hugo, Schmid Uebelhart, Sybille, Schnegg, Jean-François, Schoepfer, Alain, Seibold, Frank, Seirafi, Mariam, Semadeni, Gian-Marco, Semela, David, Senning, Arne, Sidler, Marc, Sokollik, Christiane, Spalinger, Johannes, Spangenberger, Holger, Stadler, Philippe, Steuerwald, Michael, Straumann, Alex, Straumann-Funk, Bigna, Sulz, Michael, Thorens, Joël, Tiedemann, Sarah, Tutuian, Radu, Vavricka, Stephan, Viani, Francesco, Vögtlin, Jürg, Von Känel, Roland, Vonlaufen, Alain, Vouillamoz, Dominique, Vulliamy, Rachel, Wermuth, Jürg, Werner, Helene, Wiesel, Paul, Wiest, Reiner, Wylie, Tina, Zeitz, Jonas, Zimmermann, Dorothee, Mikocka-Walus, Antonina, Pittet, Valerie, and von Känel, Roland

Published
2016
Full Text
View/download PDF

8. The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort

Author

Madanchi, Matiar, Fagagnini, Stefania, Fournier, Nicolas, Biedermann, Luc, Zeitz, Jonas, Battegay, Edouard, Zimmerli, Lukas, Vavricka, Stephan R, Rogler, Gerhard, Scharl, Michael, Anderegg, Claudia, Bauerfeind, Peter, Beglinger, Christoph, Begré, Stefan, Belli, Dominique, Bengoa, José M, Biedermann, Luc, Bigler, Beat, Binek, Janek, Blattmann, Mirjam, Boehm, Stephan, Borovicka, Jan, Braegger, Christian P, Brunner, Nora, Bühr, Patrick, Burnand, Bernard, Burri, Emanuel, Buyse, Sophie, Cremer, Matthias, Criblez, Dominique H, Saussure, Philippe de, Degen, Lukas, Delarive, Joakim, Doerig, Christopher, Dora, Barbara, Dorta, Gian, Egger, Mara, Ehmann, Tobias, El-Wafa, Ali, Engelmann, Matthias, Ezri, Jessica, Felley, Christian, Fliegner, Markus, Fournier, Nicolas, Fraga, Montserrat, Frei, Pascal, Frei, Remus, Fried, Michael, Froehlich, Florian, Funk, Christian, Furlano, Raoul Ivano, Gallot-Lavallée, Suzanne, Geyer, Martin, Girardin, Marc, Golay, Delphine, Grandinetti, Tanja, Gysi, Beat, Haack, Horst, Haarer, Johannes, Helbling, Beat, Hengstler, Peter, Herzog, Denise, Hess, Cyrill, Heyland, Klaas, Hinterleitner, Thomas, Hiroz, Philippe, Hirschi, Claudia, Hruz, Petr, Iwata, Rika, Jost, Res, Juillerat, Pascal, Brondolo, Vera Kessler, Knellwolf, Christina, Knoblauch, Christoph, Köhler, Henrik, Koller, Rebekka, Krieger-Grübel, Claudia, Kullak-Ublick, Gerd, Künzler, Patrizia, Landolt, Markus, Lange, Rupprecht, Lehmann, Frank Serge, Macpherson, Andrew, Maerten, Philippe, Maillard, Michel H, Manser, Christine, Manz, Michael, Marbet, Urs, Marx, George, Matter, Christoph, McLin, Valérie, Meier, Rémy, Mendanova, Martina, Meyenberger, Christa, Michetti, Pierre, Misselwitz, Benjamin, Moradpour, Darius, Morell, Bernhard, Mosler, Patrick, Mottet, Christian, Müller, Christoph, Müller, Pascal, Müllhaupt, Beat, Münger-Beyeler, Claudia, Musso, Leilla, Nagy, Andreas, Neagu, Michaela, Nichita, Cristina, Niess, Jan, Noël, Natacha, Nydegger, Andreas, Obialo, Nicole, Oneta, Carl, Oropesa, Cassandra, Peter, Ueli, Peternac, Daniel, Petit, Laetitia Marie, Piccoli-Gfeller, Franziska, Pilz, Julia Beatrice, Pittet, Valérie, Raschle, Nadia, Rentsch, Ronald, Restellini, Sophie, Richterich, Jean-Pierre, Rihs, Sylvia, Ritz, Marc Alain, Roduit, Jocelyn, Rogler, Daniela, Rogler, Gerhard, Rossel, Jean-Benoît, Sagmeister, Markus, Saner, Gaby, Sauter, Bernhard, Sawatzki, Mikael, Schäppi, Michela, Scharl, Michael, Schelling, Martin, Schibli, Susanne, Schlauri, Hugo, Uebelhart, Sybille Schmid, Schnegg, Jean-François, Schoepfer, Alain, Seibold, Frank, Seirafi, Mariam, Semadeni, Gian-Marco, Semela, David, Senning, Arne, Sidler, Marc, Sokollik, Christiane, Spalinger, Johannes, Spangenberger, Holger, Stadler, Philippe, Steuerwald, Michael, Straumann, Alex, Straumann-Funk, Bigna, Sulz, Michael, Thorens, Joël, Tiedemann, Sarah, Tutuian, Radu, Vavricka, Stephan, Viani, Francesco, Vögtlin, Jürg, Känel, Roland Von, Vonlaufen, Alain, Vouillamoz, Dominique, Vulliamy, Rachel, Wermuth, Jürg, Werner, Helene, Wiesel, Paul, Wiest, Reiner, Wylie, Tina, Zeitz, Jonas, and Zimmermann, Dorothee

Published
2018
Full Text
View/download PDF

9. Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohnʼs disease

Author

Lang, B. M., Biedermann, L., van Haaften, W. T., de Vallière, C., Schuurmans, M., Begré, S., Zeitz, J., Scharl, M., Turina, M., Greuter, T., Schreiner, P., Heinrich, H., Kuntzen, T., Vavricka, S. R., Rogler, G., Beerenwinkel, N., Misselwitz, B., Anderegg, Claudia, Bauerfeind, Peter, Beglinger, Christoph, Begré, Stefan, Bengoa, José M., Biedermann, Luc, Bigler, Beat, Binek, Janek, Blattmann, Mirjam, Boehm, Stephan, Borovicka, Jan, Braegger, Christian P., Brunner, Nora, Bühr, Patrick, Burnand, Bernard, Burri, Emanuel, Buyse, Sophie, Cremer, Matthias, Criblez, Dominique H., de Saussure, Philippe, Degen, Lukas, Delarive, Joakim, Doerig, Christopher, Dora, Barbara, Dorta, Gian, Egger, Mara, Ehmann, Tobias, El‐Wafa, Ali, Engelmann, Matthias, Ezri, a, Felley, Christian, Fliegner, Markus, Fournier, Nicolas, Fraga, Montserrat, Frei, Pascal, Frei, Remus, Fried, Michael, Froehlich, Florian, Funk, Christian, Furlano, Raoul Ivano, Gallot‐Lavallée, Suzanne, Geyer, Martin, Girardin, Marc, Golay, Delphine, Grandinetti, Tanja, Gysi, Beat, Haack, Horst, Haarer, Johannes, Helbling, Beat, Hengstler, Peter, Herzog, Denise, Hess, Cyrill, Heyland, Klaas, Hinterleitner, Thomas, Hiroz, Philippe, Hirschi, Claudia, Hruz, Petr, Iwata, Rika, Jost, Res, Juillerat, Pascal, Kessler Brondolo, Vera, Knellwolf, Christina, Knoblauch, Christoph, Köhler, Henrik, Koller, Rebekka, Krieger‐Grübel, Claudia, Kullak‐Ublick, Gerd, Künzler, Patrizia, Landolt, Markus, Lange, Rupprecht, Lehmann, Frank Serge, Macpherson, Andrew, Maerten, Philippe, Maillard, Michel H., Manser, Christine, Manz, Michael, Marbet, Urs, Marx, George, Matter, Christoph, McLin, Valérie, Meier, Rémy, Mendanova, Martina, Meyenberger, Christa, Michetti, Pierre, Misselwitz, Benjamin, Moradpour, Darius, Morell, Bernhard, Mosler, Patrick, Mottet, Christian, Müller, Christoph, Müller, Pascal, Müllhaupt, Beat, Münger‐Beyeler, Claudia, Musso, Leilla, Nagy, Andreas, Neagu, Michaela, Nichita, Cristina, Niess, Jan, Noël, Natacha, Nydegger, Andreas, Obialo, Nicole, Oneta, Carl, Oropesa, Cassandra, Peter, Ueli, Peternac, Daniel, Petit, Laetitia Marie, Piccoli‐Gfeller, Franziska, Pilz, Julia Beatrice, Pittet, Valérie, Raschle, Nadia, Rentsch, Ronald, Restellini, Sophie, Richterich, Jean‐Pierre, Rihs, Sylvia, Ritz, Marc Alain, Roduit, Jocelyn, Rogler, Daniela, Rogler, Gerhard, Rossel, Jean‐Benoît, Sagmeister, Markus, Saner, Gaby, Sauter, Bernhard, Sawatzki, Mikael, Schäppi, Michela, Scharl, Michael, Schelling, Martin, Schibli, Susanne, Schlauri, Hugo, Uebelhart, Sybille Schmid, Schnegg, Jean‐François, Schoepfer, Alain, Seibold, Frank, Seirafi, Mariam, Semadeni, Gian‐Marco, Semela, David, Senning, Arne, Sidler, Marc, Sokollik, Christiane, Spalinger, Johannes, Spangenberger, Holger, Stadler, Philippe, Steuerwald, Michael, Straumann, Alex, Straumann‐Funk, Bigna, Sulz, Michael, Thorens, Joël, Tiedemann, Sarah, Tutuian, Radu, Vavricka, Stephan, Viani, Francesco, Vögtlin, Jürg, Von Känel, Roland, Vonlaufen, Alain, Vouillamoz, Dominique, Vulliamy, Rachel, Wermuth, Jürg, Werner, Helene, Wiesel, Paul, Wiest, Reiner, Wylie, Tina, Zeitz, Jonas, and Zimmermann, Dorothee

Published
2018
Full Text
View/download PDF

11. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

Author

Van Assche, Gert, Dignass, Axel, Reinisch, Walter, van der Woude, C. Janneke, Sturm, Andreas, De Vos, Martine, Guslandi, Mario, Oldenburg, Bas, Dotan, Iris, Marteau, Philippe, Ardizzone, Alessandro, Baumgart, Daniel C., D'Haens, Geert, Gionchetti, Paolo, Portela, Francisco, Vucelic, Boris, Söderholm, Johan, Escher, Johanna, Koletzko, Sibylle, Kolho, Kaija-Leena, Lukas, Milan, Mottet, Christian, Tilg, Herbert, Vermeire, Séverine, Carbonnel, Frank, Cole, Andrew, Novacek, Gottfried, Reinshagen, Max, Tsianos, Epameinondas, Herrlinger, Klaus, Bouhnik, Yoram, Kiesslich, Ralf, Stange, Eduard, Travis, Simon, and Lindsay, James

Published
2010
Full Text
View/download PDF

13. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohnʼs disease

Author

Safroneeva, E., Vavricka, S. R., Fournier, N., Pittet, V., Peyrin-Biroulet, L., Straumann, A., Rogler, G., Schoepfer, A. M., Bauerfeind, Peter, Beglinger, Christoph, Begré, Stefan, Bengoa, José, Binek, Janek, Boller, Daniel, Borovicka, Jan, Braegger, Christian, Burnand, Bernard, Camara, Rafael, Criblez, Dominique, de Saussure, Philippe, Degen, Lukas, Delarive, Joakim, Ehmann, Tobias, Engelmann, Matthias, Wafa, Ali El, Felley, Christian, Frei, Alain, Frei, Remus, Fried, Michael, Friedt, Michael, Froehlich, Florian, Gallot-Lavallée, Suzanne, Gerlach, Tilman, Geyer, Martin, Girardin, Marc, Goetze, Oliver, Haack, Horst, Hediger, Serge, Hengstler, Peter, Heyland, Klaas, Janiak, Patrick, Juillerat, Pascal, Brondolo, Vera Kessler, Knoblauch, Christoph, Kullak-Ublick, Gerd A., Maillard, Michel, Manz, Michael, Marbet, Urs, Meier, Rémy, Meyenberger, Christa, Michetti, Pierre, Mottet, Christian, Müller, Christoph, Müllhaupt, Beat, Nicolet, Thierry, Nydegger, Andreas, Pache, Isabelle, Piccoli, Franziska, Pilz, Julia, Rentsch, Ronald, Rey, Jean-Pierre, Rihs, Silvia, Rogler, Daniela, Sagmeister, Markus, Sauter, Bernhard, Schaub, Niklaus, Schibli, Susanne, Seibold, Frank, Spalinger, Johannes, Stadler, Philippe, Steuerwald, Michael, Sul, Michael, Tempia-Caliera, Michela, Thorens, Joël, Vader, John-Paul, Vögtlin, Jürg, Von Känel, Roland, Wachter, Gert, Wermuth, Jürg, and Wiesel, Paul

Published
2015
Full Text
View/download PDF

14. Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients

Author

Safroneeva, E., Vavricka, S., Fournier, N., Seibold, F., Mottet, C., Nydegger, A., Ezri, J., Straumann, A., Rogler, G., Schoepfer, A. M., Bauerfeind, Peter, Beglinger, Christoph, Begré, Stefan, Bengoa, José, Binek, Janek, Boller, Daniel, Borovicka, Jan, Braegger, Christian, Burnand, Bernard, Camara, Rafael, Criblez, Dominique, de Saussure, Philippe, Degen, Lukas, Delarive, Joakim, Ehmann, Tobias, Engelmann, Matthias, Wafa, Ali El, Felley, Christian, Frei, Alain, Frei, Pascal, Frei, Remus, Fried, Michael, Froehlich, Florian, Gallot-Lavallée, Suzanne, Gerlach, Tilman, Geyer, Martin, Girardin, Marc, Goetze, Oliver, Haack, Horst, Hediger, Serge, Hengstler, Peter, Heyland, Klaas, Janiak, Patrick, Juillerat, Pascal, Brondolo, Vera Kessler, Knoblauch, Christoph, Kullak-Ublick, Gerd A., Maillard, Michel, Manser, Christine, Marbet, Urs, Manz, Michael, Meier, Rémy, Meyenberger, Christa, Michetti, Pierre, Mottet, Christian, Müller, Christoph, Müllhaupt, Beat, Nicolet, Thierry, Nydegger, Andreas, Piccoli, Franziska, Pilz, Julia, Pittet, Valérie, Rentsch, Ronald, Rey, Jean-Pierre, Rogler, Daniela, Rogler, Gerhard, Sagmeister, Markus, Sauter, Bernhard, Schaub, Niklaus, Schibli, Susanne, Schoepfer, Alain M., Seibold, Frank, Spalinger, Johannes, Stadler, Philippe, Steuerwald, Michael, Straumann, Alex, Sulz, Michael, Thorens, Joël, Vader, John-Paul, Vavricka, Stephan R., Vögtlin, Jürg, Von Känel, Roland, Wachter, Gert, Wermuth, Jürg, and Wiesel, Paul

Published
2015
Full Text
View/download PDF

18. Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): Results of a multidisciplinary international expert panel—EPACT II

Author

Mottet, Christian, Vader, John-Paul, Felley, Christian, Froehlich, Florian, Gonvers, Jean-Jacques, Juillerat, Pascal, Stockbrügger, Reinhold, Angelucci, Erika, Seibold, Frank, Michetti, Pierre, and Pittet, Valérie

Published
2009
Full Text
View/download PDF

19. Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease

Author

Mikocka-Walus, Antonina, Pittet, Valerie, Rossel, Jean-Benoît, von Känel, Roland, Anderegg, Claudia, Bauerfeind, Peter, Beglinger, Christoph, Begré, Stefan, Belli, Dominique, Bengoa, José M., Biedermann, Luc, Bigler, Beat, Binek, Janek, Blattmann, Mirjam, Boehm, Stephan, Borovicka, Jan, Braegger, Christian P., Brunner, Nora, Bühr, Patrick, Burnand, Bernard, Burri, Emanuel, Buyse, Sophie, Cremer, Matthias, Criblez, Dominique H., de Saussure, Philippe, Degen, Lukas, Delarive, Joakim, Doerig, Christopher, Dora, Barbara, Dorta, Gian, Egger, Mara, Ehmann, Tobias, El-Wafa, Ali, Engelmann, Matthias, Ezri, Jessica, Felley, Christian, Fliegner, Markus, Fournier, Nicolas, Fraga, Montserrat, Frei, Pascal, Frei, Remus, Fried, Michael, Froehlich, Florian, Funk, Christian, Ivano Furlano, Raoul, Gallot-Lavallée, Suzanne, Geyer, Martin, Girardin, Marc, Golay, Delphine, Grandinetti, Tanja, Gysi, Beat, Haack, Horst, Haarer, Johannes, Helbling, Beat, Hengstler, Peter, Herzog, Denise, Hess, Cyrill, Heyland, Klaas, Hinterleitner, Thomas, Hiroz, Philippe, Hirschi, Claudia, Hruz, Petr, Iwata, Rika, Jost, Res, Juillerat, Pascal, Kessler Brondolo, Vera, Knellwolf, Christina, Knoblauch, Christoph, Köhler, Henrik, Koller, Rebekka, Krieger-Grübel, Claudia, Kullak-Ublick, Gerd, Künzler, Patrizia, Landolt, Markus, Lange, Rupprecht, Serge Lehmann, Frank, Macpherson, Andrew, Maerten, Philippe, Maillard, Michel H., Manser, Christine, Manz, Michael, Marbet, Urs, Marx, George, Matter, Christoph, McLin, Valérie, Meier, Rémy, Mendanova, Martina, Meyenberger, Christa, Michetti, Pierre, Misselwitz, Benjamin, Moradpour, Darius, Morell, Bernhard, Mosler, Patrick, Mottet, Christian, Müller, Christoph, Müller, Pascal, Müllhaupt, Beat, Münger-Beyeler, Claudia, Musso, Leilla, Nagy, Andreas, Neagu, Michaela, Nichita, Cristina, Niess, Jan, Noël, Natacha, Nydegger, Andreas, Obialo, Nicole, Oneta, Carl, Oropesa, Cassandra, Peter, Ueli, Peternac, Daniel, Marie Petit, Laetitia, Piccoli-Gfeller, Franziska, Beatrice Pilz, Julia, Pittet, Valérie, Raschle, Nadia, Rentsch, Ronald, Restellini, Sophie, Richterich, Jean-Pierre, Rihs, Sylvia, Alain Ritz, Marc, Roduit, Jocelyn, Rogler, Daniela, Rogler, Gerhard, Rossel, Jean-Benoît, Sagmeister, Markus, Saner, Gaby, Sauter, Bernhard, Sawatzki, Mikael, Schäppi, Michela, Scharl, Michael, Schelling, Martin, Schibli, Susanne, Schlauri, Hugo, Schmid Uebelhart, Sybille, Schnegg, Jean-François, Schoepfer, Alain, Seibold, Frank, Seirafi, Mariam, Semadeni, Gian-Marco, Semela, David, Senning, Arne, Sidler, Marc, Sokollik, Christiane, Spalinger, Johannes, Spangenberger, Holger, Stadler, Philippe, Steuerwald, Michael, Straumann, Alex, Straumann-Funk, Bigna, Sulz, Michael, Thorens, Joël, Tiedemann, Sarah, Tutuian, Radu, Vavricka, Stephan, Viani, Francesco, Vögtlin, Jürg, Von Känel, Roland, Vonlaufen, Alain, Vouillamoz, Dominique, Vulliamy, Rachel, Wermuth, Jürg, Werner, Helene, Wiesel, Paul, Wiest, Reiner, Wylie, Tina, Zeitz, Jonas, and Zimmermann, Dorothee

Published
2016
Full Text
View/download PDF

22. Risk of Vaccine-Preventable Infections in Swiss Adults with Inflammatory Bowel Disease.

Author

Pittet, Laure F., Verolet, Charlotte M., Michetti, Pierre, Gaillard, Elsa, Girardin, Marc, Juillerat, Pascal, Mottet, Christian, Maillard, Michel H., Siegrist, Claire-Anne, and Posfay-Barbe, Klara M.

Subjects
INFLAMMATORY bowel diseases, CROHN'S disease, BOOSTER vaccines, PREVENTIVE medicine, TICK-borne encephalitis
Abstract

Background: Patients with inflammatory bowel disease (IBD) have a higher risk of infection and are frequently not up to date with their immunizations. Objectives: This study aims to review vaccination status and evaluate whether age, disease type, or treatment regimen could predict the absence of seroprotection against selected vaccine-preventable infection in adults with IBD. Methods: Cross-sectional study using questionnaire, immunization records review, and assessment of tetanus-specific, varicella-specific, and measles-specific immunoglobulin G concentrations. ClinicalTrials.gov: NCT01908283. Results: Among the 306 adults assessed (median age 42.7 years old, 70% with Crohn's disease, 78% receiving immunosuppressive treatment), only 33% had an immunization record available. Absence of seroprotection against tetanus (6%) was associated with increasing age and absence of booster dose; absence of seroprotection against varicella (1%) or measles (3%) was exclusively observed in younger patients with Crohn's disease. There was no statistically significant difference in immunoglobulin concentrations among treatment groups. Although vaccinations are strongly recommended in IBD patients, the frequencies of participants with at least 1 dose of vaccine recorded were low for nearly all antigens: tetanus 94%, diphtheria 87%, pertussis 54%, poliovirus 22%, measles-mumps-rubella 47%, varicella-zoster 0%, Streptococcus pneumoniae 5%, Neisseria meningitidis 12%, hepatitis A 41%, hepatitis B 48%, human papillomavirus 5%, and tick-borne encephalitis 6%. Conclusions: Although many guidelines recommend the vaccination of IBD patients, disease prevention through immunization is still often overlooked, including in Switzerland, increasing their risk of vaccine-preventable diseases. Serological testing should be standardized to monitor patients' protection during follow-up as immunity may wane faster in this population. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

25. TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update.

Author

Vulliemoz, Marianne, Brand, Stephan, Juillerat, Pascal, Mottet, Christian, Ben-Horin, Shomron, and Michetti, Pierre

Subjects
INFLAMMATORY bowel diseases, DRUG monitoring, CROHN'S disease, ULCERATIVE colitis
Abstract

Background: Anti-tumour necrosis factor-alpha (anti-TNF) antagonists have been the mainstay in the treatment of inflammatory bowel diseases (IBDs) for over 20 years. Summary: This review article aimed to provide an update on recent advances in TNF antagonist therapy for IBDs. Key Messages: Their position in the treatment algorithm has evolved to "rapid step-up therapy" or "top-down therapy" according to disease severity and patients' characteristics. Limitations of anti-TNF antagonists include loss of response in up to 30–50% of patients with or without the development of antibodies. Therapeutic drug monitoring should provide a tailored, personalized approach to this scenario. Recently, biosimilar agents have been approved for IBDs and are considered equivalent in efficacy to the originator. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

26. Update on the Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding.

Author

Restellini, Sophie, Biedermann, Luc, Hruz, Petr, Mottet, Christian, Moens, Annick, Ferrante, Marc, and Schoepfer, Alain M.

Subjects
INFLAMMATORY bowel diseases, BREASTFEEDING, BREASTFEEDING promotion, MOTHERS, PREGNANCY, MEDICAL personnel
Abstract

Inflammatory bowel disease (IBD) affects patients during their peak reproductive years. This raises important questions, in both patients and healthcare providers, regarding conception, pregnancy, and breastfeeding. Lack of information and insufficient communication among healthcare providers can leave patients with limited information and even contradictory advice. Given the fact that pregnant and/or breastfeeding IBD patients are excluded from clinical studies the evidence on many questions related to pregnancy and postpartum period is limited. However, there exists increasing data from case series and cohort studies that allows to provide clinical guidance. The overarching concept is that optimizing the mother's health is critical for optimizing the health of the unborn child and benefit of continuing medical therapy in IBD during pregnancy outweighs possible risks in most instances. This paper provides an up-to-date systematic review of the literature on IBD in pregnancy and proposes guidance to questions frequently encountered by healthcare professionals. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

27. Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus.

Author

Greuter, Thomas, Maillard, Michel H., Juillerat, Pascal, Michetti, Pierre, Seibold, Frank, Mottet, Christian, Zahnd, Nadine, Sauter, Bernhard, Schoepfer, Alain M., Rogler, Gerhard, and Vavricka, Stephan R.

Subjects
INFLAMMATORY bowel diseases, DRUG monitoring, DECISION making, CROHN'S disease, ULCERATIVE colitis
Abstract

Background: Loss of response is frequently encountered in patients with inflammatory bowel disease (IBD) treated with antitumor necrosis factor (TNF) agents. Therapeutic drug monitoring (TDM) and antidrug antibody measurement are increasingly used in this setting. Methods: To establish a consensus on the use of TDM in the context of loss of response to anti-TNFs, we performed a vote using a Delphi-style process followed by an expert panel discussion among 8 IBD specialists practicing in Switzerland, Europe. Statements were rated on an even Likert-scale ranging from 1 (strong disagreement) to 4 (strong agreement), based on expert opinion and the available literature. Results: The experts agreed on the following statements: (i) loss of response is associated with inadequate drug levels in both Crohn's disease and ulcerative colitis; (ii) best timepoint for measuring drug levels is prior to the next application (= trough levels) with different thresholds for anti-TNF agents (infliximab 5 μg/mL, adalimumab 8 μg/mL, certolizumab pegol 10 μg/mL); (iii) antidrug antibodies are predictive for loss of response; and (iv) antidrug-antibody titers and drug trough levels are key determinants in the treatment algorithm. Data about non-anti-TNF biologics were considered too limited to propose recommendations. Conclusion: A Delphi-style consensus among 8 IBD experts shows that TDM and measurement of antidrug-antibody titers are useful in the context of loss of response to anti-TNF. Optimal cutoff levels depend on the type of anti-TNF. These values are critical in the decision making process. More studies are needed to address the value of such measurements for non-anti-TNF biologics. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

31. Characteristics of non-responders to self-reported questionnaires in a large inflammatory bowel disease cohort study.

Author

Multone, Eléonore, Vader, John-Paul, Mottet, Christian, Schoepfer, Alain, Fournier, Nicolas, Burnand, Bernard, Michetti, Pierre, and Pittet, Valérie

Subjects
INFLAMMATORY bowel diseases, COHORT analysis, CROHN'S disease, ULCERATIVE colitis, SELECTION bias (Statistics)
Abstract

Background. A major threat to the validity of longitudinal cohort studies is non-response to follow-up, which can lead to erroneous conclusions. The objective of this study was to evaluate the profile of non-responders to self-reported questionnaires in the Swiss inflammatory bowel disease (IBD) Cohort. Methods. We used data from adult patients enrolled between November 2006 and June 2011. Responders versus non-responders were compared according to socio-demographic, clinical and psychosocial characteristics. Odds ratio for non-response to initial patient questionnaire (IPQ) compared to 1-year follow-up questionnaire (FPQ) were calculated. Results. A total of 1943 patients received IPQ, in which 331 (17%) did not respond. Factors inversely associated with non-response to IPQ were age >50 and female gender (OR = 0.37; p < 0.001 respectively OR = 0.63; p = 0.003) among Crohn's disease (CD) patients, and disease duration >16 years (OR = 0.48; p = 0.025) among patients with ulcerative colitis (UC). FPQ was sent to 1586 patients who had completed the IPQ; 263 (17%) did not respond. Risk factors of non-response to FPQ were mild depression (OR = 2.17; p = 0.003) for CD, and mild anxiety (OR = 1.83; p = 0.024) for UC. Factors inversely associated with non-response to FPQ were: age >30 years, colonic only disease location, higher education and higher IBD-related quality of life for CD, and age >50 years or having a positive social support for UC. Conclusions. Characteristics of non-responders differed between UC and CD. The risk of non-response to repetitive solicitations (longitudinal versus transversal study) seemed to decrease with age. Assessing non-respondents' characteristics is important to document potential bias in longitudinal studies. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

32. Acceptance of Inflammatory Bowel Disease Treatment Recommendations Based on Appropriateness Ratings: do Practicing Gastroenterologists Agree with Experts?

Author

Pittet, Valérie, Maillard, Michel H., Lauvergeon, Stéphanie, Timmer, Marjan, Michetti, Pierre, Froehlich, Florian, Burnand, Bernard, Vader, John-Paul, and Mottet, Christian

Abstract

Background: Appropriateness criteria for the treatment of Crohn's disease (CD) and ulcerative colitis (UC) have been developed by expert panels. Little is known about the acceptance of such recommendations by care providers. The aim was to explore how treatment decisions of practicing gastroenterologists differ from those of experts, using a vignette case study and a focus group. Methods: Seventeen clinical vignettes were drawn from clinical indications evaluated by the expert panel. A vignette case questionnaire asking for treatment options in 9 or 10 clinical situations was submitted to 26 practicing gastroenterologists. For each vignette case, practitioners' answers on treatments deemed appropriate were compared with panel decisions. Qualitative analysis was performed on focus group discussion to explore acceptance and divergence reasons. Results: Two hundred thirty-nine clinical vignettes were completed, 98 for CD and 141 for UC. Divergence between proposed treatments and panel recommendations was more frequent for CD (34%) than for UC (27%). Among UC clinical vignettes, the main divergences with the panel were linked to 5-aminosalicylate (5-ASA) failure assessment and to situations in which stopping treatment was the main decision. For CD, the propositions of care providers diverged from the panel in mild to moderate active disease, for which practitioners were more prone to an accelerated step-up than the panel's recommendations. Conclusions: In about one-third of vignette cases, inflammatory bowel disease treatment propositions made by practicing gastroenterologists diverged from expert recommendations. Practicing gastroenterologists may experience difficulty in applying recommendations in daily practice. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

33. Patients' information-seeking activity is associated with treatment compliance in inflammatory bowel disease patients.

Author

Pittet, Valérie, Rogler, Gerhard, Mottet, Christian, Froehlich, Florian, Michetti, Pierre, de Saussure, Philippe, Burnand, Bernard, and Vader, John-Paul

Subjects
INFLAMMATORY bowel disease treatment, PATIENT compliance, DISEASE relapse, PUBLIC health, SYMPTOMS
Abstract

Background. Despite the chronic and relapsing nature of inflammatory bowel diseases (IBD), at least 30% to 45% of the patients are noncompliant to treatment. IBD patients often seek information about their disease. Aim. To examine the association between information-seeking activity and treatment compliance among IBD patients. To compare information sources and concerns between compliant and noncompliant patients. Methods. We used data from the Swiss IBD cohort study, and from a qualitative survey conducted to assess information sources and concerns. Crude and adjusted odds ratios (OR) for noncompliance were calculated. Differences in the proportions of information sources and concerns were compared between compliant and noncompliant patients. Results. A total of 512 patients were included. About 18% ( n = 99) of patients were reported to be noncompliant to drug treatment and two-thirds ( n = 353) were information seekers. The OR for noncompliance among information seekers was 2.44 (95%CI: 1.34-4.41) after adjustment for confounders and major risk factors. General practitioners were 15.2% more often consulted ( p = 0.019) among compliant patients, as were books and television (+13.1%; p = 0.048), whereas no difference in proportions was observed for sources such as internet or gastroenterologists. Information on tips for disease management were 14.2% more often sought among noncompliant patients ( p = 0.028). No difference was observed for concerns on research and development on IBD or therapies. Conclusion. In Switzerland, IBD patients noncompliant to treatment were more often seeking disease-related information than compliant patients. Daily management of symptoms and disease seemed to be an important concern of those patients. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

34. First-Line Therapies in Inflammatory Bowel Disease.

Author

Girardin, Marc, Manz, Michael, Manser, Christine, Biedermann, Luc, Wanner, Roger, Frei, Pascal, Safroneeva, Ekaterina, Mottet, Christian, Rogler, Gerhard, and Schoepfer, Alain M.

Subjects
INFLAMMATORY bowel disease treatment, CROHN'S disease, ULCERATIVE colitis, STEROID drugs, BUDESONIDE, DISEASE risk factors
Abstract

Background and Aims: Medical therapy of inflammatory bowel disease (IBD) is becoming more complex, given the increasing choice of drugs to treat Crohn's disease (CD) and ulcerative colitis (UC). We aimed to summarize the current guidelines for first-line treatments in IBD. Methods: An extensive literature search with focus on the guidelines of the European Crohn's and Colitis Organisation for the diagnosis and treatment of CD and UC was performed. First-line treatments were defined as the following drug categories: 5-aminosalicylates, budesonide, systemic steroids, azathioprine, 6-mercaptopurine, methotrexate, infliximab, adalimumab and certolizumab pegol. The following drug categories were not included: cyclosporine and tacrolimus (not yet approved by Swissmedic for IBD treatment). Results: Treatment recommendations for the following clinically frequent situations are presented according to disease severity: ileocecal CD, colonic CD, proximal small bowel CD and perianal CD. For UC the following situations are presented: ulcerative proctitis, left-sided colitis and pancolitis. Conclusions: We provide a summary on the use of first-line therapies for clinically frequent situations in patients with CD and UC. Copyright © 2012 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

35. Treatment of Fibrostenotic and Fistulizing Crohn's Disease.

Author

Schoepfer, Alain M., Safroneeva, Ekaterina, Vavricka, Stephan R., Peyrin-Biroulet, Laurent, and Mottet, Christian

Subjects
INFLAMMATORY bowel disease treatment, ANAL fistula, IMMUNOLOGICAL adjuvants, TUMOR necrosis factor receptors, ILEOSTOMY
Abstract

The majority of Crohn's disease patients will develop a complicated disease course over time which is characterized by the occurrence of stricturing and penetrating disease. Penetrating disease comprises internal fistulas (e.g. enteroenteric) and perianal disease. A complicated disease course may be associated with considerable morbidity and professional and personal disabilities. Treatment options for fibrostenotic Crohn's disease comprise endoscopic balloon dilation, stricturoplasties and surgical resection. Treatment of symptomatic perianal fistulizing disease is based on antibiotics, immunomodulators and anti-TNF drugs. Surgical measures include fistula drainage by means of setons, temporary ileostomy or a proctectomy. The presence of internal fistulas often necessitates surgical measures. A close collaboration between the gastroenterologist and the surgeon is mandatory to solve these interdisciplinary challenges. Copyright © 2012 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

37. Appropriateness of early management of newly diagnosed Crohn's disease in a European population-based cohort*.

Author

Juillerat, Pascal, Pittet, Valérie, Mottet, Christian, Felley, Christian, Gonvers, Jean-Jacques, Vader, John-Paul, Burnand, Bernard, Froehlich, Florian, Wolters, Frank L., Stockbrügger, Reinhold W., and Michetti, Pierre

Subjects
INFLAMMATORY bowel disease treatment, INFLAMMATORY bowel diseases, INTESTINAL diseases, DIAGNOSIS, PATIENTS
Abstract

Objective. The European Panel on the Appropriateness of Crohn's disease Therapy (EPACT) has developed appropriateness criteria. We have applied these criteria retrospectively to the population-based inception cohort of Crohn's disease (CD) patients of the European Collaborative Study Group on Inflammatory Bowel Disease (EC-IBD). Material and methods. A total of 426 diagnosed CD patients from 13 European centers were enrolled at the time of diagnosis (first flare, naive patients). We used the EPACT definitions to identify 247 patients with active luminal CD. We then assessed the appropriateness of the initial drug prescription according to the EPACT criteria. Results. Among the cohort patients 163 suffered from mild-to-moderate CD and 84 from severe CD. Among the mild-to-moderate disease group, 96 patients (59%) received an appropriate treatment, whereas for 66 patients (40%) the treatment was uncertain and in one case (1%) inappropriate. Among the severe disease group, 86% were treated medically and 14% required surgery. 59 (70%) were appropriately treated, whereas for one patient (1%) the procedure was considered uncertain and for 24 patients (29%) inappropriate. Conclusion. Initial treatment was appropriate in the majority of cases for non-complicated luminal CD. Inappropriate or uncertain treatment was given in a significant minority of patients, with an increased potential risk of adverse events. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

42. Fistulizing Crohn’s Disease.

Author

Felley, Christian, Mottet, Christian, Juillerat, Pascal, Pittet, Valérie, Froehlich, Florian, Vader, John-Paul, Michetti, Pierre, and Gonvers, Jean-Jacques

Subjects
*CROHN'S disease, *FISTULA, *ANTIBIOTICS, *INFLIXIMAB, *METHOTREXATE, *CYCLOSPORINE, *TACROLIMUS
Abstract

Fistulas are common in Crohn’s disease. A population-based study has shown a cumulative risk of 33% after 10 years and 50% after 20 years. Perianal fistulas were the most common (54%). Medical therapy is the main option for perianal fistula once abscesses, if present, have been drained, and should include antibiotics (both ciprofloxacin and metronidazole) and immunomodulators. Infliximab should be reserved for refractory patients. Surgery is often necessary for internal fistulas. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

43. Severe and Steroid-Resistant Crohn’s Disease.

Author

Michetti, Pierre, Mottet, Christian, Juillerat, Pascal, Pittet, Valérie, Felley, Christian, Vader, John-Paul, Gonvers, Jean-Jacques, and Froehlich, Florian

Subjects
*CROHN'S disease, *STEROIDS, *INFLIXIMAB, *ANTINEOPLASTIC agents, *IMMUNOSUPPRESSIVE agents
Abstract

Patients with moderate-to-severe disease and patients with steroid-refractory or steroid-dependent disease differ in their management, as the latter two groups usually involve patients whose condition is less acute. Systemic corticosteroids represent the mainstay of the management of moderate-to-severe disease and remain the first-line therapy in this setting. Anti-TNF agents represent choice alternatives for patients who do not respond to steroids or in whom steroids are contraindicated. Purine analogues, methotrexate and infliximab have all shown efficacy in achieving steroid-free remission in patients with steroid-refractory or steroid-dependent disease. Other fast-acting immunosuppressors showed little benefit. Surgery may be indicated in this setting. Natalizumab may prove useful in patients refractory to infliximab and other anti-TNF agents. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

44. Upper Gastrointestinal Crohn’s Disease.

Author

Mottet, Christian, Juillerat, Pascal, Pittet, Valérie, Gonvers, Jean-Jacques, Michetti, Pierre, Vader, John-Paul, Felley, Christian, and Froehlich, Florian

Subjects
*CROHN'S disease, *ESOPHAGUS, *STOMACH, *DUODENUM, *STENOSIS
Abstract

Symptomatic gastroduodenal manifestations of Crohn’s disease are rare, with less than 4% of patients being clinically symptomatic. Gastroduodenal involvement may, however, be found endoscopically in 20% and in up to 40% of cases histologically, most frequently as Helicobacter pylori-negative focal gastritis, usually in patients with concomitant distal ileal disease. In practice, the activity of concomitant distal Crohn’s disease usually determines the indication for therapy, except in the presence of obstructive gastroduodenal symptoms. With the few data available, it seems correct to say that localized gastroduodenal disease should be treated with standard medical therapy used for more distal disease, with the exception of the galenic formulation of sulfasalazine and mesalazine with pH-dependent release. The presence of symptoms of obstruction needs aggressive therapy. If medical therapy with steroids and immunomodulatory drugs does not alleviate the symptoms, balloon dilation and surgery are the options to consider. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

45. Pregnancy and Breastfeeding in Patients with Crohn’s Disease.

Author

Mottet, Christian, Juillerat, Pascal, Pittet, Valérie, Gonvers, Jean-Jacques, Froehlich, Florian, Vader, John-Paul, Michetti, Pierre, and Felley, Christian

Subjects
*PREGNANCY, *BREASTFEEDING, *CROHN'S disease, *PREGNANT women, *THERAPEUTICS, *PATIENTS
Abstract

Crohn’s disease commonly affects women of childbearing age. Available data on Crohn’s disease and pregnancy show that women with Crohn’s disease can expect to conceive successfully, carry to term and deliver a healthy baby. Control of disease activity before conception and during pregnancy is critical, to optimize both maternal and fetal health. Generally speaking, pharmacological therapy for Crohn’s disease during pregnancy is similar to pharmacological therapy for nonpregnant patients. Patients maintained in remission by way of pharmacological therapy should continue it throughout their pregnancy. Sulfasalazine, mesalazine and corticosteroids are safe, azathioprine and 6-mercaptopurine are reasonably safe with few discordant data, infliximab seems safe as well, whereas methotrexate is contraindicated during pregnancy. During breastfeeding, mesalazine and prednisone are considered safe, azathioprine/6-mercaptopurine, budesonide and infliximab probably safe and methotrexate is contraindicated. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

46. Extraintestinal Manifestations of Crohn’s Disease.

Author

Juillerat, Pascal, Mottet, Christian, Pittet, Valérie, Froehlich, Florian, Felley, Christian, Gonvers, Jean-Jacques, Vader, John-Paul, and Michetti, Pierre

Subjects
*CROHN'S disease, *INFLAMMATORY bowel diseases, *ANKYLOSING spondylitis, *UVEITIS, *IMMUNOSUPPRESSIVE agents
Abstract

In each case of extraintestinal manifestations of Crohn’s disease, active disease, if present, should be treated to induce remission, which may positively influence the course of most concomitant extraintestinal manifestations. For some extraintestinal manifestations, however, a specific treatment should be introduced. This latter part of disease management will be discussed in this chapter, in particular for pyoderma gangrenosum, uveitis, spondylarthropathy – axial arthropathy – and primary sclerosing cholangitis, which have also been described in quiescent Crohn’s disease. Few new drugs for the treatment of extraintestinal manifestations of Crohn’s disease have been developed in the past and only the role of infliximab has increased in Crohn’s disease-related extraintestinal manifestations. Drugs specifically aimed at this treatment, stemming from a few randomized controlled studies or case series, are sulfasalazine, 5-ASA, corticosteroids, azathioprine or 6-mercaptopurine, methotrexate, infliximab, adalimumab, etanercept and cyclosporine or tacrolimus. Unfortunately, because of the paucity of data in this field, the best evidence presented and discussed in this article for the treatment of these extraintestinal manifestations is extrapolated from patients that for the most part did not suffer from Crohn’s disease. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

47. EPACT II: Project and Methods.

Author

Juillerat, Pascal, Froehlich, Florian, Felley, Christian, Pittet, Valérie, Mottet, Christian, Gonvers, Jean-Jacques, Michetti, Pierre, and Vader, John-Paul

Subjects
EVIDENCE-based medicine, INFLAMMATORY bowel diseases, CROHN'S disease, THERAPEUTICS, GASTROENTEROLOGISTS
Abstract

Building on the first European Panel on the Appropriateness of Crohn’s Disease Treatment (EPACT I) which was held in Lausanne at the beginning of March 2004, a new panel will be convened in Switzerland (EPACT II, November to December 2007) to update this work. A combined evidence- and panel-based method (RAND) will be applied to assess the appropriateness of therapy for Crohn’s disease (CD). In preparation for the meeting of experts, reviews of evidence-based literature were prepared for major clinical presentations of CD. During the meeting, an international multidis- ciplinary panel that includes gastroenterologists, surgeons and general practitioners weigh the strength of evidence and apply their clinical experience when assessing the appropriateness of therapy for 569 specific indications (clinical scenarios). This chapter describes in detail the process of updating the literature review and the systematic approach of the RAND Appropriateness Method used during the expert panel meeting. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

48. Mild-to-Moderate Active Luminal Crohn’s Disease.

Author

Michetti, Pierre, Juillerat, Pascal, Mottet, Christian, Pittet, Valérie, Gonvers, Jean-Jacques, Vader, John-Paul, Froehlich, Florian, and Felley, Christian

Subjects
CROHN'S disease, THERAPEUTICS, MICROBIAL metabolites, STEROIDS, ANTI-infective agents
Abstract

The management of luminal Crohn’s disease, the most common form of initial presentation of the disease, depends on the location and the severity of the disease. Mild-to-moderate disease represents a relatively large proportion of patients with a first flare of luminal disease, which may also be associated with perianal disease. As quality of life of these patients inversely correlates with disease activity, adequate therapy is a central goal of the overall patient management. Treatment options include mainly sulfasalazine, budesonide and systemic steroids, while the role of mesalazine and antibiotics remains controversial. The role of biological therapies has not been thoroughly evaluated in patients with mild disease. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

49. Maintenance of Medically Induced Remission of Crohn’s Disease.

Author

Gonvers, Jean-Jacques, Juillerat, Pascal, Mottet, Christian, Pittet, Valérie, Felley, Christian, Vader, John-Paul, Michetti, Pierre, and Froehlich, Florian

Subjects
CROHN'S disease, METHOTREXATE, INFLIXIMAB, DISEASE remission, THERAPEUTICS, IMMUNOSUPPRESSIVE agents, PTERIDINES, AMINOBENZOIC acids
Abstract

The natural history of Crohn’s disease is characterized by recurring flares alternating with periods of inactive disease and remission. This implies that most patients need to take medication for a large period of their life, mostly for maintenance of remission and, intermittently, additional therapy during a flare. Low-dose systemic corticosteroids are not effective in maintaining remission and should not be used for this indication. There is a trend towards a prolonged time to relapse in patients in remission who are treated with budenoside, a corticosteroid with high topical anti-inflammatory activity and low systemic activity. Azathioprine and 6-mercaptopurine are effective in maintaining remission. Maintenance benefits remain significant for patients who continued with the therapy for up to 5 years. Methotrexate has also been found to be effective in maintaining remission in Crohn’s disease in patients who have responded acutely to methotrexate. Cyclosporine has not been found to be an effective maintenance agent. Only a few studies in small numbers of patients have been published on the use of tacrolimus. There is a lack of convincing evidence of efficacy of mycophenolate mofetil. The use of anti-TNF agents may change the future approach to maintenance therapy for Crohn’s disease. Patients who responded clinically to infliximab, adalimumab and certolizumab have maintained their clinical response when receiving repeat infusions or subcutaneous injections, respectively. In patients refractory to other therapies, infliximab may be effective in maintaining remission. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

50. Maintenance of Surgically Induced Remission of Crohn’s Disease.

Author

Froehlich, Florian, Juillerat, Pascal, Pittet, Valérie, Felley, Christian, Mottet, Christian, Vader, John-Paul, Michetti, Pierre, and Gonvers, Jean-Jacques

Subjects
CROHN'S disease, POSTOPERATIVE care, IMMUNOSUPPRESSION, ENDOSCOPIC surgery, SMALL intestine, MICROBIAL metabolites, NITROIMIDAZOLES, METRONIDAZOLE
Abstract

At 1 year after a first resection, up to 80% of patients show an endoscopic recurrence, 10–20% have clinical relapse, and 5% have surgical recurrence. Smoking is one of the most important risk factors for postoperative recurrence. Preoperative disease activity and the severity of endoscopic lesions in the neoterminal ileum within the first postoperative year are predictors of symptomatic recurrence. Mesalazine is generally the first-line treatment used in the postoperative setting but still provokes considerable controversy as to its efficacy, in spite of the results of a meta-analysis. Immunosuppressive treatment (azathioprine, 6-mercaptopurine) is based on scant evidence but is currently used as a second-line treatment in postsurgical patients at high risk for recurrence, with symptoms or with early endoscopic lesions in the neoterminal ileum. Nitroimidazole antibiotics (metronidazole, ornidazole) are also effective in the control of active Crohn’s disease in the postoperative setting. Given their known toxicity, they may be used as a third-line treatment as initial short-term prevention therapy rather than in the long term. Conventional corticosteroids, budesonide or probiotics have no proven role in postoperative prophylaxis. Infliximab has not as yet been studied for use in the prevention of relapse after surgery. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results